Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Discovery of E0199: A novel compound targeting both peripheral NaV and KV7 channels to alleviate neuropathic pain

Title: Discovery of E0199: A novel compound targeting both peripheral NaV and KV7 channels to alleviate neuropathic pain
Authors: Boxuan Zhang; Xiaoxing Shi; Xingang Liu; Yan Liu; Xuedong Li; Qi Wang; Dongyang Huang; Weidong Zhao; Junru Cui; Yawen Cao; Xu Chai; Jiahao Wang; Yang Zhang; Xiangyu Wang; Qingzhong Jia
Source: Journal of Pharmaceutical Analysis, Vol 15, Iss 1, Pp 101132- (2025)
Publisher Information: Elsevier
Publication Year: 2025
Collection: Directory of Open Access Journals: DOAJ Articles
Subject Terms: Neuropathic pain; NaV channel; KV7 channel; Dorsal root ganglia; Therapeutics. Pharmacology; RM1-950
Description: This research study focuses on addressing the limitations of current neuropathic pain (NP) treatments by developing a novel dual-target modulator, E0199, targeting both NaV1.7, NaV1.8, and NaV1.9 and KV7 channels, a crucial regulator in controlling NP symptoms. The objective of the study was to synthesize a compound capable of modulating these channels to alleviate NP. Through an experimental design involving both in vitro and in vivo methods, E0199 was tested for its efficacy on ion channels and its therapeutic potential in a chronic constriction injury (CCI) mouse model. The results demonstrated that E0199 significantly inhibited NaV1.7, NaV1.8, and NaV1.9 channels with a particularly low half maximal inhibitory concentration (IC50) for NaV1.9 by promoting sodium channel inactivation, and also effectively increased KV7.2/7.3, KV7.2, and KV7.5 channels, excluding KV7.1 by promoting potassium channel activation. This dual action significantly reduced the excitability of dorsal root ganglion neurons and alleviated pain hypersensitivity in mice at low doses, indicating a potent analgesic effect without affecting heart and skeletal muscle ion channels critically. The safety of E0199 was supported by neurobehavioral evaluations. Conclusively, E0199 represents a ground-breaking approach in NP treatment, showcasing the potential of dual-target small-molecule compounds in providing a more effective and safe therapeutic option for NP. This study introduces a promising direction for the future development of NP therapeutics.
Document Type: article in journal/newspaper
Language: English
ISBN: 978-2-09-517792-8; 2-09-517792-4
Relation: http://www.sciencedirect.com/science/article/pii/S2095177924002296; https://doaj.org/toc/2095-1779; https://doaj.org/article/cb4d8e5c0ff34adba86bb98dc4d9abd9
DOI: 10.1016/j.jpha.2024.101132
Availability: https://doi.org/10.1016/j.jpha.2024.101132; https://doaj.org/article/cb4d8e5c0ff34adba86bb98dc4d9abd9
Accession Number: edsbas.2CAB3F23
Database: BASE